The role of anti-IL-5Ra treatment with benralizumab in severe asthma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article provides data on the role of anti-IL-5Rα--monoclonal antibody benralizumab in the treatment of patients with the eosinophilic phenotype of severe uncontrolled asthma. Benralizumab, through antibody-dependent cell-mediated cytotoxicity, rapidly and effectively depletes eosinophils in both peripheral blood and tissues. An analysis of the effectiveness of benralizumab (exacerbation rate, astma control, laboratory and instrumental indicators) and safety data obtained during the phase III SIROCCO/CALIMA trials and the BORA extension study provided the basis for this publication. The authors also described two cases of the use of biological therapy with anti-IL-5Ra in patients with severe asthma in real clinical practice.

Full Text

Restricted Access

About the authors

M. F Kinyaykin

Pacific State Medical University

Institute of Therapy and Instrumental Diagnostics Vladivostok, Russia

Sergey A. Danilenko

Amur State Medical Academy

Email: serdan028@mail.ru
Cand. Sci. (Med.), Assistant of the Department of Hospital Therapy with a course of Pharmacology 95, Gorky str., Blagoveshchensk 675000,Russian Federation

Yu. Yu Khizhnyak

City Outpatient Clinic № 4

Yuzhno-Sakhalinsk, Russia

I. V Naumova

Pacific State Medical University

Institute of Therapy and Instrumental Diagnostics Vladivostok, Russia

References

  1. The Global Initiative for Asthma (GINA) [Internet] (cited 2020 April 27) Available from: https://ginasthma.org
  2. Network G.A. The Global Asthma Report, Auckland, New Zealand (2018) [Internet] (cited 2020 April 27 12.05.2020) URL: http://www.globalasthmareport.org/Global%20Asthma%20Report%202018.pdf.
  3. Alzaabi A., Idrees M., Behbehani N. Crosssectional study on Asthma Insights and Management in the Gulf and Russia. Allergy Asthma Proc. 2018;39(6):430-36. doi: 10.2500/aap.2018.39.4180.
  4. Верлан Н.В. и др. Современные возможности оптимизации расходов медицинских учреждений на лечение среднетяжелой и тяжелой атопической бронхиальной астмы. Практическая иммунология. 2017;2:22-6.
  5. Респираторная медицина: руководство: в 3 т. Под ред. А.Г. Чучалина, 2-е изд., перераб. и доп. М, 2017. Т. 1. 640 с.: ил.
  6. Hekking P.P., Wener R.R., Amelink M., et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902. doi: 10.1016/j.jaci.2014.08.042.
  7. GINA Pocket Guide. Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients [Internet] (cited 2020 April 20) URL: https://ginasthma.org/wp-content/uploads/2019/04/ GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf.
  8. Emma R., Morjaria J.B., Fuochi V., et al. Mepolizumab in the management of severe eo-sinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis. 2018;12:1753466618808490. doi: 10.1177/1753466618808490.
  9. Farne H.A., Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9(9):CD010834. doi: 10.1002/14651858.CD010834.pub3.
  10. Principe S., Benfante A., Calzetta L., et al. Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. World Allergy Organ J. 2019;12(11):100081. doi: 10.1016/j.waojou.2019.100081.
  11. Agache I., Beltran J., Akdis C., et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma [published online ahead of print, 2020 Feb 8]. Allergy. 2020,10.1111/ all.14221. doi: 10.1111/all.14221.
  12. Schleich F., Brusselle G., Louis R., et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108(12):1723-32. doi: 10.1016/j.rmed.2014.10.007.
  13. Tan L.D., Bratt J.M., Godor D., et al. Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy. 2016;9:71-81. doi: 10.2147/JAA.S78049.
  14. Matucci A., Maggi E., Vultaggio A. Eosinophils, the IL-5/IL-5Ra axis, and the biologic effects of benralizumab in severe asthma. Respir Med. 2019;160:105819. doi: 10.1016/j.rmed.2019.105819.
  15. Price D., Wilson A.M., Chisholm A, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1-12. doi: 10.2147/JAA.S97973.
  16. Pelaia C., Paoletti G., Puggioni F., et al. Interleukin-5 in the Pathophysiology of Severe Asthma. Front Physiol. 2019;10:1514. doi: 10.3389/fphys.2019.01514.
  17. Yanagibashi T., Satoh M., Nagai Y., et al. Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5. Cytokine. 2017;98:59-70. doi: 10.1016/j.cyto.2016.11.011.
  18. Tan H.T., Sugita K., Akdis C.A. Novel Biologicals for the Treatment of Allergic Diseases and Asthma. Curr Allergy Asthma Rep. 2016;16(10):70. doi: 10.1007/s11882-016-0650-5.
  19. Busse W.W., Katial R., Gossage D., et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 2010;125(6):1237-44.e2. doi: 10.1016/j.jaci.2010.04.005.
  20. Castro M., Wenzel S.E., Bleecker E.R., et al. Benralizumab, an anti-interleukin 5 receptor amonoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet. Respir Med. 2014;2(11):879-90. doi: 10.1016/S2213-2600(14)70201-2.
  21. FitzGerald J.M., Bleecker E.R., Nair P., et al. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eo-sinophilic asthma (CALIMA): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-41. doi: 10.1016/S0140-6736(16)31322-8.
  22. Bleecker E.R., FitzGerald J.M., Chanez P., et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting ß2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-27. doi: 10.1016/S0140-6736(16)31324-1.
  23. Nair P., Wenzel S., Rabe K.F., et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017;376(25):2448-58. doi: 10.1056/NEJMoa1703501.
  24. Busse W.W., Bleecker E.R., FitzGerald J.M., Ferguson G.T. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet. Respir Med. 2019;7(1):46-59. Doi: 10.1016/ S2213-2600(18)30406-5.
  25. Jackson D.J., Korn S, Mathur S.K, et al. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab. Drug Saf. 2020;43(5):409-25. doi: 10.1007/s40264-020-00926-3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies